This is a standard corporate update. Key catalyst to watch is the PDUFA date for MAPLE-HCM sNDA on November 14, 2026. Monitor prescription growth trajectory for MYQORZO as a leading indicator of commercial traction.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 6 $74.84entry
- T+1 · 6mo ago 0.00%α +0.33% · $74.84
- T+5 · 6mo ago −0.04%α −1.17% · $74.81
- T+20 · 6mo ago −5.52%α −8.30% · $70.71
- T+60 · 4mo ago +3.06%α +1.00% · $77.13
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cytokinetics released a corporate presentation updating on commercial launch progress of MYQORZO (aficamten) for oHCM, positive ACACIA-HCM trial results for nHCM, and pipeline advancement. The filing is routine with no new material events or financial disclosures beyond previously announced data and launch metrics.
Key Facts
- Cash, cash equivalents and investments of approximately $1.1B as of 3/31/26
- MYQORZO launched in U.S. and China in January 2026; EU approval secured
- 680 patients prescribed MYQORZO as of 3/31/26, growing to 1,100 as of 4/30/26
- 1,400+ REMS-certified HCPs as of 3/31/26; average 2.4 prescriptions per HCP
- sNDA for aficamten monotherapy (MAPLE-HCM) under FDA review with PDUFA date November 14, 2026
- Positive topline results from ACACIA-HCM (nHCM) presented; KCCQ-CSS LSM difference 3.0 (p=0.021) and pVO2 LSM difference 0.67 mL/kg/min (p=0.003)
- Eligible to draw up to $175M from Royalty Pharma loan; up to $150M option for ulacamten pivotal trial funding
- Omecamtiv mecarbil Phase 3 COMET-HF enrolling; ulacamten Phase 2 AMBER-HFpEF enrolling
Financial Impact
No new financial impact; reiterates ~$1.1B cash position and access to up to $325M additional capital
Risk Factors
- Regulatory risk for MAPLE-HCM sNDA and potential label restrictions
- Commercial adoption slower than expected; competition from CAMZYOS
- Dilution risk from potential capital raises despite existing cash and loan facilities
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-206420 |
| Document: d124879d8k.htm | 0001193125-26-206420 |
| Document: 0001193125-26-206420-index-headers.html | 0001193125-26-206420 |
| Document: 0001193125-26-206420-index.html | 0001193125-26-206420 |
| Document: 0001193125-26-206420.txt | 0001193125-26-206420 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers